dr. ledermann on response to rucaparib in recurrent ovarian cancer
Published 4 years ago • 322 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
6:12
rucaparib for recurrent ovarian cancer
-
1:20
dr. ledermann on rationale for ariel3 trial in ovarian cancer
-
1:42
dr. ledermann on rucaparib maintenance in ovarian cancer
-
1:19
dr. ledermann on phase iii ariel3 results in ovarian cancer
-
1:21
rucaparib may improve pfs in patients with ovarian cancer
-
2:09
rucaparib maintenance for recurrent ovarian carcinoma
-
7:10
jonathan a ledermann – maintenance treatment for recurrent ovarian carcinoma
-
1:42
phase iii results for rucaparib in ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
1:57
dr. ledermann on parp inhibitors in maintenance therapy for ovarian cancer
-
5:18
rucaparib for ovarian cancer
-
5:11
defining rucaparib’s value in recurrent ovarian cancer
-
7:34
parp inhibition’s role in recurrent ovarian cancer
-
3:07
rucaparib maintenance and monotherapy for ovarian cancer: trial updates
-
0:45
dr. coffman on safety concerns with parp inhibitors in ovarian cancer
-
6:49
platinum-sensitive relapsed ovarian cancer: rucaparib
-
1:29
dr. monk on the fda approval of maintenance rucaparib in ovarian cancer
-
1:14
dr. coleman on benefit of rucaparib in ovarian cancer